|
Gene: ZNF586 |
Gene summary for ZNF586 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF586 | Gene ID | 54807 |
Gene name | zinc finger protein 586 | |
Gene Alias | ZNF586 | |
Cytomap | 19q13.43 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9NXT0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54807 | ZNF586 | A018-E-020 | Human | Colorectum | FAP | 3.37e-06 | -2.69e-01 | -0.2034 |
54807 | ZNF586 | F034 | Human | Colorectum | FAP | 2.89e-08 | -1.93e-01 | -0.0665 |
54807 | ZNF586 | EEC-subject4 | Human | Endometrium | EEC | 1.33e-12 | 5.37e-01 | -0.2571 |
54807 | ZNF586 | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.70e-05 | 7.06e-01 | 0.3371 |
54807 | ZNF586 | RNA-P17T-P17T-4 | Human | Lung | IAC | 5.83e-07 | 8.51e-01 | 0.343 |
54807 | ZNF586 | RNA-P17T-P17T-8 | Human | Lung | IAC | 3.37e-03 | 5.75e-01 | 0.3329 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF586 | SNV | Missense_Mutation | novel | c.859G>C | p.Glu287Gln | p.E287Q | Q9NXT0 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
ZNF586 | SNV | Missense_Mutation | novel | c.947G>A | p.Arg316Lys | p.R316K | Q9NXT0 | protein_coding | tolerated(0.31) | benign(0.241) | TCGA-C8-A26X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
ZNF586 | SNV | Missense_Mutation | c.551N>C | p.Gly184Ala | p.G184A | Q9NXT0 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
ZNF586 | SNV | Missense_Mutation | rs767980205 | c.409C>T | p.Leu137Phe | p.L137F | Q9NXT0 | protein_coding | tolerated(0.38) | probably_damaging(0.914) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF586 | insertion | Frame_Shift_Ins | novel | c.747dupT | p.Ile250TyrfsTer2 | p.I250Yfs*2 | Q9NXT0 | protein_coding | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ZNF586 | insertion | Frame_Shift_Ins | novel | c.1061_1062insCGGAGGC | p.Ala355GlyfsTer4 | p.A355Gfs*4 | Q9NXT0 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
ZNF586 | insertion | Frame_Shift_Ins | novel | c.1063_1064insAGGTGGGCGGATCA | p.Ala355GlufsTer15 | p.A355Efs*15 | Q9NXT0 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
ZNF586 | SNV | Missense_Mutation | c.491N>T | p.Ser164Leu | p.S164L | Q9NXT0 | protein_coding | tolerated(0.24) | possibly_damaging(0.459) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ZNF586 | SNV | Missense_Mutation | c.602C>T | p.Ser201Phe | p.S201F | Q9NXT0 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF586 | SNV | Missense_Mutation | c.52N>A | p.Glu18Lys | p.E18K | Q9NXT0 | protein_coding | deleterious(0) | benign(0.048) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |